Professor Richard Haynes
Research groups
Richard Haynes
DM, MRCP
Professor of Renal Medicine and Clinical Trials
- MSc in Global Health Science module 8 lead: Clinical Trials and Meta-Analysis
Richard Haynes did his pre-clinical medical studies in Cambridge before moving to Oxford for his clinical studies and qualified in 2000. He came to the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) for a period of “out of programme” research in 2006 to work on the HPS2-THRIVE trial with Prof Jane Armitage. He completed his training in renal medicine in 2011 and was appointed as an honorary consultant at the Oxford Kidney Unit.
Recent publications
-
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Journal article
Mayne K. et al, (2024), Nephrology Dialysis Transplantation
-
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) for hospitalised patients with COVID-19: prospective meta-analysis of randomised trials
Journal article
LANDRAY M. et al, (2024), The Lancet Diabetes and Endocrinology
-
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.
Journal article
Mayne KJ. et al, (2024), Clin J Am Soc Nephrol
-
Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England.
Journal article
Pessoa-Amorim G. et al, (2024), Trials, 25
-
EFFECTS OF EMPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE FROM JAPAN: EXPLORATORY ANALYSES FROM EMPA-KIDNEY
Journal article
HERRINGTON W., (2024), Clinical and Experimental Nephrology